1. Home
  2. Press release
Oct 06, 2022 20:16 JST

Source: AIM Vaccine Co., Ltd.

AIM Vaccine, a Major Player in the Chinese Vaccine Industry, Successfully Listed on the Main Board of SEHK

HONG KONG, Oct 06, 2022 - (ACN Newswire) - AIM Vaccine Co., Ltd. ("AIM Vaccine" or the "Company", together with its subsidiaries, the "Group", stock code: 06660.HK), the second largest vaccine company in China in terms of 2021 approved lot release volume (excluding COVID-19 vaccines), was successfully listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK") today, with a board lot of 200 H shares each. The debut of AIM Vaccine's stock price was very outstanding on 6 October. The share price closed at HK$16.66, up 3.09%.

Goldman Sachs (Asia) L.L.C., China International Capital Corporation Hong Kong Securities Limited, China Securities (International) Corporate Finance Company Limited and Macquarie Capital Limited are the Joint Sponsors, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers. BOCI Asia Limited, CMB International Capital Limited, Futu Securities International (Hong Kong) Limited, and Tiger Brokers (HK) Global Limited are the Joint Bookrunners and Joint Lead Managers. ICBC International Capital Limited is Joint Bookrunner, ICBC International Securities Limited and Livermore Holdings Limited are the Joint Lead Managers.

The Company said that the listing of AIM Vaccine in Hong Kong marks a key milestone and unfolds a new chapter in the Company's development. Looking ahead, AIM Vaccine will continue to strive to access to quality industry resources to expand and optimize its business. The Company will keep abreast of the most advanced platform technologies and innovation trends, accelerating the development of vaccine candidates and continuing to enrich its product portfolio, solidifying and expanding market leadership by increasing sales and marketing efforts for approved vaccine products and commercializing new products, thereby realizing its mission to "develop and manufacture top quality vaccines to safeguard the health of the world", becoming a world-class vaccine company in the global vaccine market and creating greater value for shareholders.


Source: AIM Vaccine Co., Ltd.
Sectors: BioTech, Healthcare & Pharm

Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Latest Release


TOPVISION Launches Prospectus for Listing Transfer from LEAP to the ACE Market
Nov 27, 2024 05:53 JST

TOYOTA GAZOO Racing FULLY PREPARED FOR DAKAR 2025
Nov 26, 2024 17:55 JST

Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan
Nov 26, 2024 15:50 JST

Fujitsu develops Policy Twin, a new digital twin technology to maximize effectiveness of local government policies for solving societal issues
Nov 26, 2024 10:51 JST

TOYOTA GAZOO Racing reinforces WRC line-up with youth and experience for 2025
Nov 25, 2024 17:10 JST

Toyota Submits Progress Report on Recurrence Prevention Measures
Nov 25, 2024 15:43 JST

TOPVISION Launches Prospectus for Transfer Listing from LEAP to the ACE Market
Nov 25, 2024 15:00 JST

MHI Thermal Systems Receives Order from Aisan Industry for Aquifer Thermal Energy Storage System for Its New Anjo Plant
Nov 25, 2024 14:18 JST

Oracle Red Bull Racing Driver Max Verstappen Wins Fourth Consecutive F1 Drivers' World Championship
Nov 25, 2024 11:55 JST

Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025
Nov 22, 2024 11:00 JST

NaaS Q3 2024 Recap: Strategic Shifts and Tech Innovations for Growth
Nov 21, 2024 22:59 JST

Honda Unveils Demonstration Production Line for All-Solid-State Batteries Located in Sakura City, Tochigi Prefecture, Japan
Nov 21, 2024 15:35 JST

Deadline to Lead in Securities Fraud Lawsuit Against Humacyte, Inc. (HUMA) is January 17, 2025 - Contact Kaplan Fox & Kilsheimer LLP
Nov 21, 2024 09:00 JST

ALL Study Groups Using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study
Nov 20, 2024 23:05 JST

Start of Demonstration Test of Two-Phase Direct-to-Chip Cooling in the Air-Cooled Data Center
Nov 20, 2024 15:30 JST

Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Nov 20, 2024 11:51 JST

Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Nov 20, 2024 10:24 JST

Kingsoft Announces 2024 Third Quarter Results
Nov 19, 2024 18:54 JST

NTT and Olympus Joint Demonstration Shows IOWN APN's Low-latency Capability Can Be Used for Real-time Diagnosis and Treatment on a Remote Server to Realize World's First Cloud Endoscopy System
Nov 19, 2024 15:30 JST

Supercomputer Fugaku retains first place worldwide in HPCG and Graph500 rankings
Nov 19, 2024 09:02 JST
 More Latest Release >>

Related Release

AIM Vaccine Announces Global Offering Results, Offer Price of HK$16.16 per H Share
October 05 2022 18:55 JST
 
AIM Vaccine Announces Proposed Listing on the Main Board of SEHK
September 23 2022 17:06 JST
 
Phase I Clinical Trial of AIM mRNA COVID-19 Vaccine (LVRNA009) Won the Praise of the Industry for High Safety and Well Tolerance
January 12 2022 10:26 JST
 
More Press release >>